These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36470873)

  • 21. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
    Wang L; Yu Z; Wang S; Guo Z; Sun Q; Lai L
    Eur J Med Chem; 2022 Dec; 244():114803. PubMed ID: 36209629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fast and Effective Prediction of the Absolute Binding Free Energies of Covalent Inhibitors of SARS-CoV-2 Main Protease and 20S Proteasome.
    Zhou J; Saha A; Huang Z; Warshel A
    J Am Chem Soc; 2022 May; 144(17):7568-7572. PubMed ID: 35436404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.
    Kneller DW; Li H; Phillips G; Weiss KL; Zhang Q; Arnould MA; Jonsson CB; Surendranathan S; Parvathareddy J; Blakeley MP; Coates L; Louis JM; Bonnesen PV; Kovalevsky A
    Nat Commun; 2022 Apr; 13(1):2268. PubMed ID: 35477935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docking Paradigm in Drug Design.
    Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV
    Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
    Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.
    Sasi VM; Ullrich S; Ton J; Fry SE; Johansen-Leete J; Payne RJ; Nitsche C; Jackson CJ
    Biochemistry; 2022 Nov; 61(22):2495-2505. PubMed ID: 36326185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apigenin analogues as SARS-CoV-2 main protease inhibitors:
    Farhat A; Ben Hlima H; Khemakhem B; Ben Halima Y; Michaud P; Abdelkafi S; Fendri I
    Bioengineered; 2022 Feb; 13(2):3350-3361. PubMed ID: 35048792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
    Zhang S; Krumberger M; Morris MA; Parrocha CMT; Kreutzer AG; Nowick JS
    Eur J Med Chem; 2021 Jun; 218():113390. PubMed ID: 33812315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of SARS-CoV-2 3CL
    Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.
    Ma C; Xia Z; Sacco MD; Hu Y; Townsend JA; Meng X; Choza J; Tan H; Jang J; Gongora MV; Zhang X; Zhang F; Xiang Y; Marty MT; Chen Y; Wang J
    J Am Chem Soc; 2021 Dec; 143(49):20697-20709. PubMed ID: 34860011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Refaey RH; El-Ashrey MK; Nissan YM
    Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
    Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
    Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
    Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.